Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E Ahn, Xin Tian, David Ipe, et al.
Blood
|
December 1, 2020
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines
Christopher Pleyer, Mir A Ali, Jeffrey I Cohen, et al.
Journal for Immunotherapy of Cancer
|
November 28, 2022
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
Matthew G Cyr, Maissa Mhibik, Junpeng Qi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2023
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Anfal Alsadhan, Jonathan Chen, Erika M Gaglione, et al.
Blood Advances
|
May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Maissa Mhibik, Erika M Gaglione, David Eik, et al.
Blood
|
March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
Clare Sun, Pia Nierman, Ellen K Kendall, et al.
Blood
|
January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Sivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.
Leukemia & Lymphoma
|
March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study
Sanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood Cancer Discovery
|
November 15, 2021
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
Arthur L Shaffer, James D Phelan, James Q Wang, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E Ahn, Xin Tian, David Ipe, et al.
Blood
|
December 1, 2020
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines
Christopher Pleyer, Mir A Ali, Jeffrey I Cohen, et al.
Journal for Immunotherapy of Cancer
|
November 28, 2022
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
Matthew G Cyr, Maissa Mhibik, Junpeng Qi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2023
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Anfal Alsadhan, Jonathan Chen, Erika M Gaglione, et al.
Blood Advances
|
May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Maissa Mhibik, Erika M Gaglione, David Eik, et al.
Blood
|
March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
Clare Sun, Pia Nierman, Ellen K Kendall, et al.
Blood
|
January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Sivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.
Leukemia & Lymphoma
|
March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study
Sanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood Cancer Discovery
|
November 15, 2021
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
Arthur L Shaffer, James D Phelan, James Q Wang, et al.
Page
of 2